Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Eiger BioPharmaceuticals, Inc. (EIGRQ) had Revenue of $15.77M for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$15.77M
Net Income	$-74.96M
Cost of Goods Sold	$0.02M
Gross Profit	$15.75M
Operating Expenses	$87.56M
Operating Income	$-71.79M
Non-Operating Income/Expense	$-3.17M
Pre-Tax Income	$-74.96M
Normalized Pre-Tax Income	$-74.96M
Income after Taxes	$-74.96M
Income from Continuous Operations	$-74.96M
Consolidated Net Income/Loss	$-74.96M
Normalized Income after Taxes	$-74.96M
EBIT	$-71.79M
EBITDA	$-72.62M
Weighted-Average Shares Outstanding (Basic)	1.48M
Weighted-Average Shares Outstanding (Diluted)	1.48M
Earnings per Share (EPS) (Basic)	$-50.78
Earnings per Share (EPS) (Diluted)	$-50.78
Balance Sheet Financials
Current Assets	$37.84M
Property, Plant, and Equipment	$0.63M
Long-Term Assets	$0.99M
Total Assets	$38.83M
Current Liabilities	$53.28M
Long-Term Debt	--
Long-Term Liabilities	--
Total Liabilities	$53.28M
Common Equity	$-14.46M
Tangible Shareholders Equity	$-14.46M
Shareholders Equity	$-14.46M
Common Shares Outstanding	1.48M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-74.55M
Cash Flow from Investing Activities	$74.23M
Cash Flow from Financial Activities	$0.04M
Beginning Cash	$25.80M
End Cash	$25.44M
Increase/Decrease in Cash	$-0.36M
Stock-Based Compensation	$5.01M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.71
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	-2.84
Gross Margin	99.85%
Operating Margin	-455.12%
EBIT Margin	-455.12%
EBITDA Margin	-460.43%
Pre-Tax Profit Margin	-475.22%
Profit Margin	-475.26%
Free Cash Flow	$-74.78M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.41
Inventory Turnover	0.02
Receiveable Turnover	9.38
Days Sales in Receivables	38.92
Return on Equity	518.49%
Return on Tangible Equity	518.49%
Return on Assets	-193.07%
Return on Investments	518.49%
Book Value Per Share	$-9.78
Free Cash Flow per Share	$-50.67
Operating Cash Flow per Share	$-50.51

Data from Zacks Investment Research, Inc.